Detailed entry information

Protein Information (annotations from UniProt)

Database IDHIV0002209
UniProt IDO14939
Primary gene name(s)PLD2
Synonym gene name(s)unknown
Protein namePhospholipase D2
Protein functionMay have a role in signal-induced cytoskeletal regulation and/or endocytosis. {ECO:0000250}.
Subcellular locationMembrane {ECO:0000250};
Peripheral membrane protein {ECO:0000250}.
ECO codeClick here for more information.
Amino acid sequence
FASTA format: O14939
Gene Ontology
(Biological Process)
Complete annatation
cell motility [GO:0048870];
cytoskeleton organization [GO:0007010];
Fc-gamma receptor signaling pathway involved in phagocytosis [GO:0038096];
inositol lipid-mediated signaling [GO:0048017];
lipid catabolic process [GO:0016042];
phosphatidic acid biosynthetic process [GO:0006654];
small GTPase mediated signal transduction [GO:0007264];
synaptic vesicle recycling [GO:0036465]
Gene Ontology
(Molecular Function)
Complete annatation
N-acylphosphatidylethanolamine-specific phospholipase D activity [GO:0070290];
phosphatidylinositol binding [GO:0035091];
phospholipase D activity [GO:0004630]
Gene Ontology
(Cellular Component)
Complete annatation
cytosol [GO:0005829];
endoplasmic reticulum membrane [GO:0005789];
Golgi apparatus [GO:0005794];
plasma membrane [GO:0005886];
presynapse [GO:0098793]
Protein-protein interaction111354
Phylogenetic treeO14939
HIV replication factor status Zhou et al., Cell. Host. Microbe., 2008
      unknown
Brass et al., Science, 2008
      unknown
Smith et al., J. Immunol, 2010
      unknown
Interferon-stimulated
gene status
Lu et al., J. Virol., 2011
      Folds changes 8h: unknown; Folds changes 16h: unknown; Tested: unknown;
Schoggins JW and Rice CM, Curr. Opin. Virol., 2011
      Targeted viruses: unknown
      Viral life cycle: unknown
      Mechanism related to antiviral activity: unknown
Anti-viral restriction factor Liu et al., Retrovirology, 2011
      unknown (Triplicates)

Gene Expression Profile       top

            Up-regulated;            Down-regulated

For brief introduction to each study, please go to the help page.

Gene expression during HIV latency

(1). Mohammadi et al., PLoS Pathog., 2014

Differentially expressed transcripts (Pairwise) during latency and subsequent viral reactivation using several agents - Primary CD4+ T-cell based model


DMSO: Dimethyl suloxyde (negative control) - 0.0033% final
SAHA: Vorinostat (Histone deacetylase inhibitor) - 0.5 μM
CD3: TCR Stimulation by IL-2+ antiCD3/anti-CD28 antibodies
IL7: Interleukin-7 based stimulation
DISU: Disulfiram (alcohol dehydrogenase inhibitor) - 0.5 μM
AZA: 5-azacytidine (AZA; DNA methylation inhibitor) - 1 μM
Experimental Condition Log2 Fold Change P value Adjusted P value
AZA vs. CD3-1.217692394242440.0003178347412884360.00133437471328672
AZA vs. DISU-0.01317208555385910.9589561042361960.996649735504266
AZA vs. IL7-0.3284662747276980.09494756751195120.823917492865654
AZA vs. SAHA-0.185799595004130.4526939310637470.794031686857682
DISU vs. CD31.191237156645190.001573540970415180.00609600529119465
DISU vs. IL7-0.3253299914492670.202612733655790.579690066399894
DISU vs. SAHA-0.1700672486320040.5646488097439880.858451336287789
DMSO vs. AZA0.06940187170697860.6864210752240951
DMSO vs. CD31.27461608227930.0001156937691401130.000513078196083544
DMSO vs. DISU0.0804818083714850.7442515159926140.96918036409561
DMSO vs. IL7-0.3903658448875350.03395365121779810.377471454357159
DMSO vs. SAHA-0.2604393850114380.2758105123743910.624209244068189
HIV vs. Mock in Activation0.3239066666062820.6066512716666280.999983755607037
HIV vs. Mock in Latency0.132571976427050.4321566157894180.999834320637052
IL7 vs. CD30.8944722428203110.006707824040435130.0214482460249212
SAHA vs. CD31.008469143860880.005261260598748980.0149288640977494
SAHA vs. IL70.1397523108762130.5716139569247970.777944094139075
(2). Iglesias-Ussel et al., J. Virol., 2013

Up and Downregulated transcripts during Latency (Latently infected CD4+ T cells vs Uninfected)- Primary CD4+Tcell based model
Log2 Fold Change P Value
unknown unknown

Gene expression during HIV infection and replication

(1). Imbeault et al., PloS Pathog., 2012

Transcriptomic profiling of HIV-1 infected CD4+ T cells - Primary CD4+ T cells
Experiment type Log2 Fold Change P Value Adjusted P Value
Infected vs. Mock unknown unknown unknown
Infected vs. Bystander unknown unknown unknown
(2). Lefebvre et al., J. Virol., 2011

Transcriptome analysis of T-cell line (Sup T1)
Log2 Fold Change unknown
(3). Li et al., J. Immunol., 2013

Lymphatic tissue
Acute Fold Change Acute P Value Asymt Fold Change Asypt P Value AIDS Fold Change AIDS P Value
unknown unknown unknown unknown unknown unknown
(4). Chang et al., MBio., 2011

Transcriptome analysis of T-cell line (Sup T1)

Derived from Sherrill-Mix et al., BMC Retrovirol., 2015 cross validation
Up-regulated (True) TRUE
(5). Sherrill-Mix et al., BMC Retrovirol., 2015

Deep RNA-seq analysis of primary human T cell infected with low passage HIV isolate HIV89.6 - Primary CD4+ T cell based
Test Status Log2 Fold Change P Value
OK -0.546501 0.151603
(6). Rotger et al., PLoS Pathog., 2010

Genome-wide mRNA expression of CD4+ T cells from HIV-infected patient
(Genes differentially expressed (at adjusted p<0.01) according to the empirical Bayes approach)
Log2 Fold Change P Value
unknown unknown

Proteomic/Transcriptomics studies indicating differentially expressed genes mediated by HIV

(1). Greenwood et al., Elife, 2016

Activated (CD3/CD28) Primary human CD4+ T cells infected with pNL4-3-dE-EGFP. The table shows the complete (unfiltered) TMT (tandem mass tag)-based proteomic time course dataset
6 h 24 h 48 h 72 h RTi
unknown unknown unknown unknown unknown
(2). Navare et al., Virology, 2012

SUP-T1 cell line
FC-4hpi P-value FC-8hpi P-value FC-20hpi P-value Category
unknown unknown unknown unknown unknown unknown unknown
(3). Hyrcza et al., J. Virolo., 2007

Primary human CD4+ and CD8+ T Cells
Affymetrix Prob ID Fold Change In CD8? Category
unknown unknown unknown unknown

Protein Overview       top

Drug-protein Interaction       (annotations from DrugBank)      top

Drugbank ID Drug Name Drug Status Pharmacological Action Drug Action
DB00122 Choline approved, nutraceutical unknown product of

Protein Secondary Structure       (annotations from PDB)      top

not found

HIV-1 Interaction       (annotations from NCBI HIV-1 Interaction Database)      top

HIV Partner Interaction Type PubMed
Envelope surface glycoprotein gp120 activates 17627030

Metabolic/Signalling Pathway       (annotations from KEGG database)      top

Pathway Accession Number Description
hsa00564 Glycerophospholipid metabolism - Homo sapiens (human)
hsa00565 Ether lipid metabolism - Homo sapiens (human)
hsa01100 Metabolic pathways - Homo sapiens (human)
hsa04014 Ras signaling pathway - Homo sapiens (human)
hsa04024 cAMP signaling pathway - Homo sapiens (human)
hsa04071 Sphingolipid signaling pathway - Homo sapiens (human)
hsa04072 Phospholipase D signaling pathway - Homo sapiens (human)
hsa04144 Endocytosis - Homo sapiens (human)
hsa04666 Fc gamma R-mediated phagocytosis - Homo sapiens (human)
hsa04724 Glutamatergic synapse - Homo sapiens (human)
hsa04912 GnRH signaling pathway - Homo sapiens (human)
hsa05231 Choline metabolism in cancer - Homo sapiens (human)
Menu